Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulodexide - Alfasigma

Next Previous
X
Search
Drug Profile

Sulodexide - Alfasigma

Alternative Names: 3GS; Glucoronylglucosaminoglycan sulphate; KRX-101; Sulodexide Gelcaps; Sulonex; Vessel; vessel due F

Latest Information Update: 15 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Alfasigma; Keryx Biopharmaceuticals
  • Class Antifibrotics; Antithrombotics; Glycosaminoglycans; Heparins; Urologics; Vascular disorder therapies
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis; Vascular disorders
  • Phase III Venous insufficiency
  • Discontinued Diabetic nephropathies; Glomerulonephritis; Kidney disorders; Pulmonary fibrosis; Venous thromboembolism

Most Recent Events

  • 01 Aug 2023 Alfasigma terminates a phase-III SuloPrima trial in Venous insufficiency in Czech Republic (PO) (EudraCT2021-002311-64)
  • 01 Oct 2021 Phase-III clinical trials in Venous insufficiency in Czech Republic (PO) (EudraCT2021-002311-64)
  • 05 May 2021 Phase-III clinical trials in Venous insufficiency in Slovakia (PO, Capsule) (EudraCT2020-000110-15)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top